These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 38274793)

  • 1. Bispecific antibodies in indolent B-cell lymphomas.
    Radhakrishnan VS; Davies AJ
    Front Immunol; 2023; 14():1295599. PubMed ID: 38274793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on bi-specific monoclonal antibodies for blood cancers.
    Shouse G
    Curr Opin Oncol; 2023 Sep; 35(5):441-445. PubMed ID: 37551951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mosunetuzumab and the emerging role of T-cell-engaging therapy in follicular lymphoma.
    Matarasso S; Assouline S
    Future Oncol; 2023 Oct; 19(31):2083-2101. PubMed ID: 37882361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era.
    González Barca E
    Front Immunol; 2022; 13():909008. PubMed ID: 35928819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting.
    Liu X; Zhao J; Guo X; Song Y
    J Hematol Oncol; 2023 Aug; 16(1):90. PubMed ID: 37537626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.
    Keating GM
    Drugs; 2010 Jul; 70(11):1445-76. PubMed ID: 20614951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bispecific antibodies for the treatment of lymphomas: Promises and challenges.
    Schuster SJ
    Hematol Oncol; 2021 Jun; 39 Suppl 1():113-116. PubMed ID: 34105818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mosunetuzumab: First Approval.
    Kang C
    Drugs; 2022 Jul; 82(11):1229-1234. PubMed ID: 35947358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual target dilemma: navigating epcoritamab vs. glofitamab in relapsed refractory diffuse large B-cell lymphoma.
    Davis JA; Granger K; Sakowski A; Goodwin S; Herbst A; Smith D; Hendrickson L; Nachar VR
    Expert Rev Hematol; 2023; 16(12):915-918. PubMed ID: 37982732
    [No Abstract]   [Full Text] [Related]  

  • 11. [Drug approval: Mosunetuzumab - third-line therapy in follicular lymphoma].
    Gondran C; Ysebaert L
    Bull Cancer; 2022 Nov; 109(11):1105-1106. PubMed ID: 36167561
    [No Abstract]   [Full Text] [Related]  

  • 12. Thinking "outside the germinal center": Re-educating T cells to combat follicular lymphoma.
    Kambhampati S; Shouse G; Danilov AV
    Blood Rev; 2023 Sep; 61():101099. PubMed ID: 37173225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges and solutions to superior chimeric antigen receptor-T design and deployment for B-cell lymphomas.
    Gao J; Dahiya S; Patel SA
    Br J Haematol; 2023 Oct; 203(2):161-168. PubMed ID: 37488074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Follicular lymphoma: The long and winding road leading to your cure?
    Gordon MJ; Smith MR; Nastoupil LJ
    Blood Rev; 2023 Jan; 57():100992. PubMed ID: 35908982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.
    Bannerji R; Arnason JE; Advani RH; Brown JR; Allan JN; Ansell SM; Barnes JA; O'Brien SM; Chávez JC; Duell J; Rosenwald A; Crombie JL; Ufkin M; Li J; Zhu M; Ambati SR; Chaudhry A; Lowy I; Topp MS
    Lancet Haematol; 2022 May; 9(5):e327-e339. PubMed ID: 35366963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evaluation of glofitamab, the first fixed-duration bispecific antibody for relapsed or refractory large B-cell lymphomas.
    Polgarova K; Trneny M
    Expert Opin Biol Ther; 2024; 24(1-2):7-13. PubMed ID: 38305755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.
    Hutchings M; Morschhauser F; Iacoboni G; Carlo-Stella C; Offner FC; Sureda A; Salles G; Martínez-Lopez J; Crump M; Thomas DN; Morcos PN; Ferlini C; Bröske AE; Belousov A; Bacac M; Dimier N; Carlile DJ; Lundberg L; Perez-Callejo D; Umaña P; Moore T; Weisser M; Dickinson MJ
    J Clin Oncol; 2021 Jun; 39(18):1959-1970. PubMed ID: 33739857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment.
    Bock AM; Nowakowski GS; Wang Y
    Curr Treat Options Oncol; 2022 Feb; 23(2):155-170. PubMed ID: 35182296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacist perspectives on emerging T cell-engaging bispecific therapies in cancer therapeutics.
    Moore DC; Digiantonio N; Oxencis CJ; Taucher KD
    Am J Health Syst Pharm; 2024 Jul; 81(14):574-582. PubMed ID: 38394329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current status and future prospects of diffuse large B-cell lymphoma treatment].
    Yamaguchi M
    Rinsho Ketsueki; 2022; 63(9):1126-1134. PubMed ID: 36198538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.